简繁EN
Antengene

Company Introduction

3D Medicines, Inc. is a commercial-stage biopharmaceutical company with a mission to help people with cancer live longer and better. Envisioning a future when cancer is managed as a chronic disease, 3D Medicines focuses on the development of differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both biological macromolecule and chemotherapeutic small-molecule drugs, as well as a professional team capable of global development, registration and commercialization operation.

MORE

March 2024

04
04
04
04
04
04
04
04
04
04
04
04
March 2020
October 2020
November 2020
December 2020
January 2021
March 2021
April 2021
December 2022
December 2022
August 2023
August 2023
March 2024

PipelineThe company has established a multi-core collaborative clinical pipeline

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

Candidate
Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase Ⅱ

Phase Ⅲ

NDA

Partner

  • Envafolimab
  • PD-L1
  • Worldwide

  • MSI-H/dMMR advanced cancer (mono, 2L+)

  • Advanced BTC (combo with chemo vs. chemo, 1L)

  • NSCLC (Adjuvant/Neo-adjuvant therapy, 1L)

  • G/GEJ advanced cancer (combo with chemo, 1L)

  • TMB-H advanced cancer (mono, 2L+)

  • EC (mono and combo with lenvatinib, 2L+)

  • HCC, CRC, NSCLC (combo with BD0801)

  • Microsatellite stable CRC (combo with cetuximab+/- Fruquintinib, standard treatment failure)

  • dMMR advanced solid tumors (mono, 2L+)

MORE

  • 3D189
  • WT1
  • Greater China

  • Multiple indications

  • AML

MORE

  • 3D229
  • GAS6/AXL
  • Greater China

  • Healthy Volunteers

MORE

  • 3D1001
  • COX-2

  • Post-surgical dental pain/cancer pain

  • Haihe Biopharma Group

MORE

  • 3D1002
  • EP-4
  • China

  • Cancer pain / osteoarthritis

MORE

  • 3D185
  • FGFR1/2/3
  • Worldwide

  • Locally advanced or metastatic solid tumors

MORE

  • 3D011
  • TKI prodrug
  • Worldwide

  • Advanced malignant solid tumors

MORE

  • 3D1015
  • RDC
  • 全球

  • mCRPC

MORE

  • 3D124
  • mRNA
  • 全球

  • Multiple Indications

MORE

  • 3D197
  • CD47
  • Greater China

  • Multiple indications

MORE

  • 3D057
  • CD3+PD-L1
  • Greater China + Worldwide Priority Transfer right

  • Multiple indications

  • Y-Biologics

MORE

  • 3D059
  • WT1肿瘤疫苗
  • Worldwide

  • Multiple indications

MORE

  • 3D062
  • KRAS
  • Worldwide

  • Multiple indications

MORE

Pipeline

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D1015
  9. 3D124
  10. 3D197
  11. 3D057
  12. 3D059
  13. 3D062

CEO MESSAGE



As a young biotechnology company, our goal is to achieve several milestones and make profitable innovation. We are steadfast in strengthening our internal discovery capability and conducting pivotal clinical trials to address unmet medical needs to provide more treatment options for cancer patients.



we are confident that we are well-positioned to achieve our vision of transforming cancer from a terminal illness into a manageable chronic disease. We have a robust pipeline of differentiated cancer therapies that address unmet medical needs in the future and offer significant valuation to patients, physicians, and payers. We have a talented and passionate team of scientists, clinicians and professionals who are committed to delivering on our promise of bringing hope and healing to millions of cancer patients around the world




-- John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines Inc.

MORE

Company News

MORE


Copyright © 3D Medicines Inc. All Rights Reserved